



This is a repository copy of *Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why?*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/197173/>

Version: Accepted Version

Article:

Brittain, G. orcid.org/0000-0002-9903-7203, Coles, A.J., Giovannoni, G. orcid.org/0000-0001-9995-1700 et al. (7 more authors) (2023) Autologous haematopoietic stem cell transplantation for immune-mediated neurological diseases: what, how, who and why? *Practical Neurology*, 23 (2). pp. 139-145. ISSN 1474-7758

<https://doi.org/10.1136/pn-2022-003531>

This article has been accepted for publication in *Practical Neurology*, 2022 following peer review, and the Version of Record can be accessed online at <http://dx.doi.org/10.1136/pn-2022-003531>. © Authors (or their employer(s)) 2022. Reuse of this manuscript version (excluding any databases, tables, diagrams, photographs and other images or illustrative material included where a another copyright owner is identified) is permitted strictly pursuant to the terms of the Creative Commons Attribution-Non Commercial 4.0 International (<https://creativecommons.org/licenses/by-nc/4.0/>)

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don't have to license any derivative works on the same terms. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



eprints@whiterose.ac.uk
<https://eprints.whiterose.ac.uk/>

Autologous haematopoietic stem cell transplantation for immune mediated neurological diseases – what, how, who and why

Authors

Gavin Brittain^{1,2}, Alasdair Coles³, Gavin Giovannoni⁴, Paolo A. Muraro⁵, Jacqueline Palace⁶, Jennifer Petrie⁷, Elisa Roldan⁸, Neil Scolding^{10,11,12}, John A. Snowden^{*8,9} and Basil Sharrack^{*1,2}

¹Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK

²Department of Neurology and Sheffield NIHR Neuroscience BRC, Sheffield Teaching Hospitals NHS Foundation Trust and University of Sheffield, Sheffield, UK

³ Department of Clinical Neuroscience, School of Medicine, University of Cambridge, Cambridge, UK

⁴ Blizard Institute, Barts and The London School of Medicine and Dentistry, London, UK

⁵ Department of Brain Sciences, Imperial College London, London, UK.

⁶Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford University Hospitals NHS Trust and Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

⁷Clinical Trials Research Unit, University of Sheffield, Sheffield, UK

⁸Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK

⁹Department of Oncology & Metabolism, Medical School, University of Sheffield, Sheffield, UK

¹⁰University of Bristol, Bristol, UK

¹¹Gulu University Faculty of Medicine, Uganda

¹²Neurology Department, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK

Acknowledgements

*The authors BS and JS contribute to this article equally as senior authors and on behalf of Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). We acknowledge the ADWP for its support in providing updated registry data and all EBMT member centers and their clinicians, data managers and patients for their valuable contributions to the EBMT registry'.

This research was supported / funded by the NIHR Sheffield Biomedical Research Centre (BRC) / NIHR Sheffield Clinical Research Facility (CRF). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care (DHSC).

StarMS: 16/126/26 is funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership.

Figure 1 created with BioRender.com.

Abstract

In carefully selected patients, autologous haematopoietic stem cell transplantation is a safe, highly effective and cost-saving treatment modality for treatment-resistant, and potentially treatment-naïve, immune-mediated neurological disorders. Although the evidence base has been growing in the last decade, limited understanding has led to confusion, mistrust and increasing use of health tourism. In this article, we discuss what autologous haematopoietic stem cell transplantation is, which immune-mediated conditions can be treated with it, how to select patients, what are the expected outcomes and potential adverse effects, and how cost-effective this treatment is.

Background

Haematopoietic stem cell transplantation (HSCT) is a broad description for a process involving the ablation and reconstitution of the myeloid and lymphoid systems aiming to eradicate malignant cells, or, when used for the treatment of autoimmune disease, to develop a new and 'tolerant' immune repertoire. Haematopoietic stem cells can be obtained from the peripheral blood following a short course of a growth factor, alone or in combination with a cytotoxic treatment, either from the affected patient (autologous) or a closely matched donor (allogeneic). Autologous HSCT (aHSCT) is currently used to 're-boot' the autoreactive immune systems in patients with specific immune-mediated neurological disorders, mainly multiple sclerosis (MS) but also chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), neuromyelitis optica (NMO), stiff person syndrome (SPS) and myasthenia gravis (MG) (1). Allogeneic HSCT is rarely used in the treatment of immune-mediated neurological disorders. Mesenchymal stem cells (MSCs) are another type of stem cells that have shown initial therapeutic promise, although in neurological disease this has not yet been borne out in clinical trials (2).

Although aHSCT is increasingly used as an evidence-based treatment modality for immune-mediated neurological disorders (1), many neurologists do not feel prepared to discuss it with their patients or counsel them about it (3). Patient organisations perceive the pace of the neurological community in adopting aHSCT to be slow, resulting in patients resorting to health tourism, sometimes from unregulated providers (3, 4).

Various misconceptions within both patient and clinician communities have further complicated this field. For some patients, their primary clinicians' unwillingness to discuss aHSCT has led to self-directed 'research' using a mixture of social media outputs, blogs, private providers' literature or informal discussions with other patients (5). The online literature offered by private providers has limited information regarding the treatment process and follow up care. Some claim that the treatment is risk-free and advertise it as a uniformly accepted cure (6). Nine of the top ten indications listed as being appropriate for transplantation by such providers are not recommended by any regulatory body and are not immune mediated conditions. These unsupported journeys often lead to poor quality information and decision making, particularly when patients are desperate for what they perceive to be a high efficacy treatment which is being withheld. This results in patients undergoing this intensive and relatively expensive procedure by unregulated providers with variable quality and safety and therefore exacerbating the unease and misunderstanding within the medical community.

How

Appropriately selected patients, outlined below, undergo detailed evaluation by a multi-disciplinary team with experience in stem cell transplantation, including an experienced neurologist, a transplant haematologist and a specialist transplant nurse, working in a centre with appropriate accreditation. This approach leads to an increased opportunity for better patient selection and engagement and

therefore better treatment outcomes. The nature of the treatment, its success rate and potential adverse events including, but not limited to, infections, chemotherapy toxicity, prolonged hospital stay, and treatment-related mortality (TRM), are discussed with patients. Fertility conservation procedures are discussed, and actioned, and patients are counselled that the intensity of the procedure, the period of isolation and the reduced peri-procedure mobility can make their condition transiently worse.

The procedure (see figure 1) has 3 stages; mobilisation and stem cell harvesting, conditioning and stem cell infusion and follow up. Whilst several treatment regimens exist, see table 1, we will refer to the most commonly used regimen in MS (1, 7). 'Mobilisation' of peripheral blood stem cells (PBSC) from the bone marrow to the peripheral blood is achieved by administering cyclophosphamide (Cy, commonly dosed at 2g/m^2) usually as a day case or, sometimes, as a single night admission, followed by subcutaneous injections of granulocyte colony-stimulating factor (G-CSF). Cyclophosphamide counters potential G-CSF induced disease activity (8). Thereafter, PBSC are 'harvested' by apheresis. The 'conditioning' phase is delivered as an inpatient during which a short, but intensive course of cytotoxic chemotherapy, often combined with T-cell depleting 'serotherapy', commonly rabbit- or horse- derived anti-thymocyte globulin (ATG), are administered via a central venous access device. Unmanipulated autologous PBSC are then re-infused (usually via the same central venous access device) on 'day 0', and the patient receives supportive care measures, including prophylactic anti-infectives, transfusions of red cells and platelets, monitoring of fluid status, electrolytes, weight and bladder function. Engraftment occurs, typically, 2-3 weeks after re-infusion of PBSC. Whilst ex-vivo CD34+ selected autologous haemopoietic stem cells have been used (9), this extra step adds additional cost, may increase infection risk and delays time to engraftment and is not used routinely in clinical practice(1). The total inpatient stay usually lasts for 4 weeks during which the patient is cared for in protective isolation. The patient is then discharged home but is advised to shield for a period of three months whilst antifungal, anti-viral drugs and anti-pneumocystis prophylaxis are continued for variable periods according to centre protocols. Screening for CMV and EBV by PCR is dependent on centre protocol and may be performed for the first three months (and longer if necessary), with specific pre-emptive treatment delivered as required.

Patients are counselled that the intensity of the procedure and reduced mobility during the periods of isolation and shielding can contribute to profound fatigue, increased spasticity and reduced ability to ambulate in the immediate aftermath of the transplant. Specific guidelines have been produced to support pre and re-habilitation alongside routine transplant care (10).

Table 1: Currently used conditioning regimens.

Intensity	Examples of conditioning regimen (1, 7)	Mechanism of action	Comment
High	Busulfan, cyclophosphamide and ATG (BuCyATG).	Myeloablative	Now rarely used in immune-mediated neurological disorders outside of clinical trials. Data confirms long-term efficacy in RRMS, but higher risk of TRM and adverse effects.
Intermediate	Carmustine (BCNU) 300 mg/m^2 , etoposide 800 mg/m^2 , cytarabine-arabinoside 800 mg/m^2 and	Lympho-myeloablative	The most widely used regimens recommended by

	melphalan 140 mg/m ² and rabbit or horse ATG (BEAM-ATG).		the European Society for Blood and Marrow Transplantation for MS (1).
	Cyclophosphamide 200 mg/kg and rabbit ATG (Cy-ATG) with steroid cover.	Lymphoablative	
Low	Chemotherapy alone (e.g cyclophosphamide at mobilisation and conditioning)	Lymphoablative	Limited data suggests lower efficacy.

Whilst serious adverse events can occur, none have been reported in the largest randomised controlled trial for MS (11). The most common adverse events were febrile neutropenia, electrolyte disturbances and transient elevated transaminases. Infections (typically urinary tract and respiratory infections) occurred at a rate of 0.19 per patient per year, similar to that encountered with the use of standard disease-modifying treatments (DMTs). aHSCT is a one-off elective procedure with most of the risk being concentrated to the peri-transplant period. TRM, defined as mortality within 100 days, has improved since the early studies in MS with a reduction from 1.3% between 2001 and 2007 to 0.2% between 2012 to 2017 and thereafter (8, 12). This reduction has been attributed to better patient selection and the use of intermediate-intensity treatment regimens, and, arguably, compares favourably with the associated early mortality risks of common elective surgical procedures such as cholecystectomy, hip and knee replacement (1%, 1.20% and 0.9% respectively) (13, 14) or with the reported longer-term mortality risks related to use of some high efficacy disease modifying treatments such as natalizumab and alemtuzumab (0.13% and 0.18% respectively) (15, 16). Where previous DMTs have been used, including B and T cell depleting therapies, safety does not differ between previous agents (17).

Beyond 3 months, the majority of follow up can be delivered in specialist neurological clinics, with, ideally, input from neurologists and transplant haematologists. As with any HSCT procedure, long term follow-up in a specialist setting is also required for advice on vaccination and to monitor for secondary autoimmune diseases, most commonly thyroid disease (10%) or immune thrombocytopenic purpura (ITP) (2-3%), infertility, malignancy, and other 'late effects' (18). Whilst secondary malignancy has been occasionally associated with the use of aHSCT for other indications, in the largest cohort of 507 patients, no cases occurred (19). Healthy babies have been born to both male and female patients post aHSCT, although large cohorts of long-term data are lacking (20).

Although aHSCT use was restricted during the peaks of the high transmission rates of the COVID-19 pandemic, it is now being offered to suitable patients with careful monitoring (21). A recent review of European Society for Blood and Marrow Transplantation (EBMT) registry data showed that non-relapse mortality rate (which is defined as death from any cause) between 2015 and 2020 has remained stable (12).

It is recommended that procedures are performed in centres accredited by JACIE (Joint Accreditation Committee of International Society for Cellular Therapy, ISCT, and EBMT), or equivalent organisations providing minimum quality standards for haematopoietic cellular therapy. As per other transplant indications, patient data should be routinely reported in accordance with regulatory standards to the EBMT and/or equivalent international registries, where specific minimal essential data (MED) forms have been developed for MS and other autoimmune diseases to enable audit of activity and retrospective analyses to be undertaken.

Who

As of 2021, the EBMT registry has collected data for 3502 patients treated specifically with HSCT since 1994 for various severe autoimmune disorders (ADs), including neurological, rheumatological, gastroenterological and other AD indications (12). The majority had MS (1875) and other immune-mediated neurological disorders included CIDP (65), NMO (27), MG (10) and SPS (8) (1, 12).

Initial reports of treatment success were limited to case reports. Despite the lack of commercial interest, a few phase II trials and one phase III trial (in RRMS) have now been completed across a range of disorders (table 2). In these trials patients typically had either highly active or treatment-resistant diseases, making the outcomes even more notable. Trial outcomes, including measures of disability, reversal of positive antibody status and freedom from relapse or progression, have been improving steadily as patient selection and treatment regimens are refined (22).

Table 2: Selected data from patients undergoing autologous haematopoietic stem cell transplantation for various immune-mediated neurological disorders.

	MS (11, 12, 23-26)	CIDP (27, 28)	NMO (22, 29)	SPS (30)
Reported number of procedures ⁺	1875 in EBMT centres (mainly Europe)	64	27	36
Freedom from disease activity [*]	78.5% (RRMS)	73-83%	48-90%	47%
TRM	0.2%	No reported mortality	No reported mortality	No reported mortality
Follow up	Mean of 34 months [^]	Median of 54 months [^]	Median 47 months (29) and 60 months (22), respectively.	Mean of 42 months [^]
Trial status	Few phase II trials and one phase III trial completed, further phase III trials ongoing (Star-MS)	Phase II trial complete	Phase II trial complete	Phase II trial complete

TRM = transplant related mortality. ⁺ clinical trials and EBMT registry data or case reports. ^{*}Specific to individual diseases; MS = no evidence of disease activity (freedom from MRI activity, disability worsening and relapses), CIDP = freedom from ongoing immunotherapy or relapses, NMO = progression free survival, SPS = freedom from ongoing immunotherapy or relapses. [^]in the largest reported studies, detailed in 'Patient outcomes'.

Why

Patient outcomes

Initial trials in MS concentrated on patients in the progressive phase of the disease with high levels of disability. A shift to treating patients whose primary pathology is thought to be active inflammation has subsequently occurred with results showing high levels of freedom from disease activity and lower TRM (table 2). The previous experience should not be overlooked; pooled analysis of trials with a majority of progressive patients (either primary or secondary, both active and inactive) demonstrated a 24.8% chance of disability progression at 2-year (31). Whilst it is not possible to compare this mixed meta-analysis with studies of populations containing just secondary progressive MS, they are of interest when comparing to a 20% risk of disability progression, at a shorter time point of 6 months, with Siponimod therapy and a 45% risk of progression at 2 years with interferon- beta-1a (32, 33). Suppression of relapses, but not disability progression or brain atrophy, have been demonstrated (34, 35), which may indicate a future role for aHSCT in patients

with progressive MS with active inflammation (see case report on SPMS), although further well-designed randomised trials are required.

For highly active RRMS the high degree of efficacy demonstrated in the only prospective clinical trial to date is impressive (11, 23). High rates of progression free survival (90.29%) and relapse free survival (84.6%) at 5 years were observed in the MIST trial (aHSCT vs clinician selected DMT, including natalizumab but not other high efficacy DMTs with a mean follow up of 2.8 years). The open label cross over design led to 31/51 patients switching from DMT to aHSCT. Due to the historic nature of the study, the only high efficacy DMT included was natalizumab and the relapse rate of 64.8% at 1 year in the standard treatment arm was higher than expected. Despite this, reductions in MRI activity, improvements in clinical assessment and across various domains of quality of life were also seen. TRM was 0%. This study provided the first direct comparison between aHSCT and traditional DMTs. No evidence of disease activity (NEDA), defined as absence of clinical progression, relapses and MRI activity, was proven in 78.5% of patients post aHSCT and 2.97% in the DMT treatment arm at 5 years. aHSCT is now recommended with Grade I evidence as standard of care for patients with highly active RRMS who fail DMTs (1, 36). Further phase 3 randomised controlled trials are currently recruiting, including in the UK (Star-MS, ISRCTN88667898), where aHSCT is being compared to high efficacy DMTs in treatment resistant RRMS or treatment naïve patients with rapidly evolving severe MS (37).

A retrospective review of a cohort of patients with 'aggressive RRMS' (defined as clinical and radiological features in keeping with an aggressive clinical course and poor prognostic markers) who were treated first line with aHSCT showed a NEDA rate of 100% over a median follow up of 30 months (26). Progression of brain atrophy, in patients with 'aggressive RRMS' who receive aHSCT, reverts to that of healthy controls (9).

Whilst the trial data for CIDP is at an earlier stage, similar promising results have been seen in patients resistant to at least two first-line therapies with 83% freedom from ongoing immunosuppressive therapies and stable or improving clinical examination, improvement in independent ambulation from 33% to 83% and improvement of various domains of neurophysiological examination (27). Mean follow up was 54 months and there were no transplant-related deaths. aHSCT is recommended as a clinical option for patients with IVIg resistant or dependent CIDP (1).

A retrospective review of 16 patients with treatment resistant NMO, who were treated with aHSCT utilising a mixture of low and intermediate intensity conditioning regimens, demonstrated a progression free survival of 48% over a median follow up of 47 months (29). 100% of patients remained seropositive and TRM was 0%. However, a subsequent small (n=12) open-label trial in treatment-resistant NMO patients, utilising an intermediate conditioning regimen with adjuvant rituximab and plasmapheresis, led to a 90% progression free survival at 5 years, 81% reversal of antibody status, and improvements across various quality of life domains over a mean follow up of 57 months (22). There were no transplant-related deaths.

Stiff person syndrome responds variably to aHSCT (30, 38). Trial experience shows that whilst 74% of patients entered an immunosuppressive free period, 47% of these relapsed within 3.5 years. Symptom load reduced and ambulation appeared to improve in the responders.

Whilst a trial has not yet been successfully reported for patients with MG, collated case series provides preliminary data that aHSCT may provide sustained remission from symptoms, freedom from immunotherapy and, in some cases, reversal of antibody status (39).

Case vignette – RRMS failing DMTs

A 27-year-old female presented with sensory symptoms in 2009 followed by speech disturbance in 2011. An MRI showed evidence of demyelination and cerebrospinal fluid (CSF) analysis demonstrated unmatched oligoclonal bands supporting a diagnosis of RRMS. Treatment with Glatiramer Acetate did not prevent further relapses 2013 and 2014. Following escalation to fingolimod further relapses with MRI evidence of disease activity in January and April 2015 contributed to an EDSS of 4. aHSCT (Cy 2m/m² + G-CSF for stem cell mobilisation followed by Cy 200mg/kg + rabbit ATG 6mg/kg with methylprednisolone cover) was provided in October 2015. Just over 12 months post procedure her EDSS had dropped to 1.5 and, although the post-transplant period was significant for hypothyroidism, her condition has remained clinically and radiologically quiescent ever since. The patient has had no further symptoms she attributes to MS, runs frequently, including a half-marathon, and has successfully delivered a healthy child following IVF 2.5 years post-transplant.

Case vignette - treatment naive RRMS

A 33-year-old female experienced numbness of both legs resulting in falls in March 2013, followed by weakness and incoordination of the left leg one year later with incomplete recovery. Left optic neuritis was followed by sensorimotor symptoms of her left leg in July and October 2014, respectively. An MRI showed evidence of demyelination and CSF demonstrated unmatched oligoclonal bands supporting a diagnosis of RRMS. DMT was planned but before initiation, two further relapses occurred: in February 2015 (right leg weakness) and April 2015 (right-sided ataxia) contributing to an EDSS of 6.5. Repeated imaging demonstrated several enhancing lesions. With criteria for rapidly evolving severe RRMS being met, aHSCT (Cy 2m/m² + G-CSF for stem cell mobilisation followed by Cy 200mg/kg + rabbit ATG 6mg/kg with methylprednisolone cover) was performed in May 2015 with no adverse effects. EDSS improved to 3.0 in June 2016 and was 2.5 in October 2021 with exercise tolerance being unlimited. Two children were conceived and born uneventfully by normal vaginal delivery in 2016 and 2019.

Case vignette – SPMS

A 30-year-old male had an episode of transverse myelitis in early 2000 with incomplete recovery, followed by a subacute sensory lower limb disturbance in late 2000. A subacute episode of lower limb weakness which improved with steroids then occurred in late 2007. Following this, investigation with brain and spinal MRI and CSF examination resulted in a diagnosis of RRMS, with an EDSS of 6.0. Interferon beta-1a was commenced but a further relapse occurred in 2008. Decline in mobility, balance and sphincter control thereafter prompted a diagnosis of secondary progressive MS with an EDSS 6.5 in 2012. Two further relapses with multiple enhancing lesions on brain and spinal MRI scans occurred in 2012, following which he underwent aHSCT (Cy 2m/m² + G-CSF for stem cell mobilisation followed by Cy 200mg/kg + rabbit ATG 6mg/kg with methylprednisolone cover). The post-transplant period was complicated by neutropenic septicaemia requiring intensive care support, a tracheostomy and prolonged inpatient neurorehabilitation. Whilst further evidence of clinical and MRI activity has been absent, disability level has gradually progressed with the latest EDSS, in May 2022, being 8.0.

Case vignette – Treatment resistant CIDP

A 49-year-old female was diagnosed with CIDP in 2005. The initial phase of illness ran an aggressive course with progression to tetraplegia within the same year. Although some clinical improvement occurred, over time her illness became refractory to treatment with glucocorticoids, immunoglobulin and plasma exchange. In 2013 further deterioration, despite ongoing immunomodulation, resulted in limited hand function and significant lower limb weakness requiring

the use of a walking stick and bilateral ankle-foot orthoses. In 2014, some 9 years post-diagnosis, treatment with aHSCT (Cy 2m/m² + G-CSF for stem cell mobilisation followed by Cy 200mg/kg + rabbit ATG 6mg/kg with methylprednisolone cover) was provided with no significant adverse effects. Since then, there is freedom from immunosuppression, an ability to walk independently for 2 miles, and remarkable sustained improvements in neurophysiological parameters and objective clinical examination.

Health economics

Immune-mediated neurological disorders cause a wide range of financial implications including medical and non-medical health care-related costs and loss of productivity. Detailed analysis of the direct comparison of the costs of aHSCT versus ongoing immunomodulation treatment for neurological conditions within the NHS is required.

Single centre estimate of the one-off cost of aHSCT in the NHS is approximately £35,000 (40). Whilst not a direct comparison, as list prices do not include administration, follow up or any negotiated discounts, the BNF prices of highly efficacious DMTs include natalizumab at £13,560 per annum, ocrelizumab at £19,160 per annum and alemtuzumab and cladribine at £56,360 and £28,662 for two-year courses, respectively (41). Whilst the cost of the former two depend on the duration of the treatment, the latter two are considered as complete courses in most patients. In CIDP, the cost of continued IVIg use for UK patients has been reported to be £49,430 per annum (42).

The potential elimination of the need for ongoing use of DMTs and/or immunosuppression and reduction in relapses and disability accumulation, the improved productivity of the affected patient and the reduction in the cost of medical and non-medical interventions, makes this treatment modality a very attractive option. Health technology reports for NHS Wales and NHS Scotland found aHSCT in treatment resistant or highly active RRMS to be both more effective and less costly than DMTs (43, 44).

Conclusion

aHSCT is a relatively safe, cost-effective procedure for carefully selected patients with refractory or highly active immune-mediated neurological disorders. Whilst its peri-procedure burden and potential risks have to be considered carefully, in contrast to most DMTs it is a one-off treatment with no cumulative toxicity or treatment burden. Based on current evidence it is recommended as a standard of care for patients with highly active relapsing-remitting MS failing DMTs and a clinical option for treatment naïve patients with aggressive MS, patients with progressive MS and active inflammation, and some patients with treatment-resistant CIDP, NMO, MG and SPS. Further studies are required to evaluate its utility as a first-line therapy. To ensure quality of care, patients should be treated in a transplant centre with JACIE (or equivalent) accreditation. Where possible, patients should be enrolled in clinical trials which will not only further our understanding of this treatment, but also support the development of greater numbers of specialised centres with combined experience, ultimately targeting this intensive but effective treatment option appropriately and easing the limited availability and unmet clinical needs within our health services.

Key points

1. aHSCT should be offered as standard of care to patients with active RRMS failing disease-modifying treatment and considered as a treatment option in treatment naïve patients with rapidly evolving severe MS.
2. The use of aHSCT should be considered in patients with other treatment-resistant immune-mediated neurological disease.

3. Patients should be appropriately selected, and treatment should take place in accredited centres with appropriate cross-disciplinary teams and as part of clinical trials, where relevant.
4. aHSCT may represent a long-term economic saving.

Further reading

1. Sharrack B, Saccardi R, Alexander T et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE). *Bone Marrow Transplant*. 2020 Feb;55(2):283-306.
2. Greco R, Alexander T, Burman J et al. Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. *Bone Marrow Transplant*. 2021 Jul;56(7):1493-1508.
3. Ismail A, Sharrack B, Saccardi R et al. Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation. *Curr Opin Support Palliat Care*. 2019 Dec;13(4):394-401.
4. Sharrack B, Petrie J, Coles A, Snowden J A. Is stem cell transplantation safe and effective in multiple sclerosis? *BMJ* 2022; 377.




Figure 1: Representation of the usual treatment pathway for autologous stem cell transplantation. G-CSF = granulocyte colony-stimulating factor.

References

1. Sharrack B, Saccardi R, Alexander T, Badoglio M, Burman J, Farge D, et al. Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Acc. Bone Marrow Transplantation. 2020;55(2):283-306.
2. Uccelli A, Laroni A, Ali R, Battaglia MA, Blinkenberg M, Brundin L, et al. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. *The Lancet Neurology*. 2021;20(11):917-29.
3. Julian K, Yuhasz N, Rai W, Salerno JA, Imitola J. Complications from "Stem Cell Tourism" in Neurology. *Annals of Neurology*. 2020;88(4):661-8.
4. von Wunster B, Bailey S, Wilkins A, Marks DI, Scolding NJ, Rice CM. Advising patients seeking stem cell interventions for multiple sclerosis. *Pract Neurol*. 2018;18(6):472-6.
5. Petersen A, Tanner C, Munsie M. Navigating the cartographies of trust: how patients and carers establish the credibility of online treatment claims. *Sociology of Health & Illness*. 2019;41(S1):50-64.
6. Connolly R, O'Brien T, Flaherty G. Stem cell tourism--a web-based analysis of clinical services available to international travellers. *Travel Med Infect Dis*. 2014;12(6 Pt B):695-701.
7. Burt RK, Farge D, Saccardi R, Quiglet K, Han X, Snowden JA. Autologous HSCT conditioning regimens for autoimmune diseases. In: Burt RK, Farge D, Ruiz MA, Saccardi R, A. SJ, editors. *Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases*. 1st Edition ed: CRC Press; 2021. p. 8.
8. Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, Saccardi R. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. *Nature Reviews Neurology*. 2017;13(7):391-405.
9. Atkins HL, Bowman M, Allan D, Anstee G, Arnold DL, Bar-Or A, et al. Immunoablation and autologous haematopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. *The Lancet*. 2016;388(10044):576-85.
10. Roberts F, Hobbs H, Jessop H, Bozzolini C, Burman J, Greco R, et al. Rehabilitation Before and After Autologous Haematopoietic Stem Cell Transplantation (AHSCT) for Patients With Multiple Sclerosis (MS): Consensus Guidelines and Recommendations for Best Clinical Practice on Behalf of the Autoimmune Diseases Working Party, Nurses Group, and Patient Advocacy Committee of the European Society for Blood and Marrow Transplantation (EBMT). *Front Neurol*. 2020;11:556141.
11. Burt RK, Balabanov R, Burman J, Sharrack B, Snowden JA, Oliveira MC, et al. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. *JAMA*. 2019;321(2):165-74.
12. Alexander T, Greco R. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). *Bone Marrow Transplantation*. 2022.
13. Mytton J, Daliya P, Singh P, Parsons SL, Lobo DN, Lilford R, et al. Outcomes Following an Index Emergency Admission With Cholecystitis: A National Cohort Study. *Annals of Surgery*. 2021;274(2):367-74.
14. Penfold CM, Whitehouse MR, Blom AW, Judge A, Wilkinson JM, Sayers A. A comparison of comorbidity measures for predicting mortality after elective hip and knee replacement: A cohort study of data from the National Joint Registry in England and Wales. *PLOS ONE*. 2021;16(8):e0255602.
15. Coles AJ, Arnold DL, Bass AD, Boster AL, Compston DAS, Fernández Ó, et al. Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. *Therapeutic Advances in Neurological Disorders*. 2021;14:175628642098213.

16. Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I, et al. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). *Journal of Neurology, Neurosurgery, and Psychiatry*. 2020;91(6):660-8.
17. Kvistad SAS, Burman J, Lehmann AK, Tolf A, Zjukovskaja C, Melve GK, et al. Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHST. *Journal of Neurology, Neurosurgery & Psychiatry*. 2022;93(8):844.
18. Willison AG, Ruck T, Lenz G, Hartung HP, Meuth SG. The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis. *Journal of Neurology*. 2022;269(7):3937-58.
19. Burt RK, Han X, Quigley K, Helenowski IB, Balabanov R. Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis. *Journal of Neurology*. 2022;269(5):2513-26.
20. Chatterton S, Withers B, Sutton IJ, Milliken ST, Ma DD, Moore JJ, et al. Pregnancy post autologous stem cell transplant with BEAM conditioning for multiple sclerosis. *Mult Scler*. 2021;27(13):2112-5.
21. Greco R, Alexander T, Burman J, Del Papa N, De Vries-Bouwstra J, Farge D, et al. Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. *Bone Marrow Transplantation*. 2021;56(7):1493-508.
22. Burt RK, Balabanov R, Han X, Burns C, Gastala J, Jovanovic B, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica. *Neurology*. 2019;93(18):e1732-e41.
23. Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, et al. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS. *Neurology*. 2017;88(9):842-52.
24. Burman J, Iacobaeus E, Svenningsson A, Lycke J, Gunnarsson M, Nilsson P, et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience. *J Neurol Neurosurg Psychiatry*. 2014;85(10):1116-21.
25. Das J, Sharrack B, Snowden JA. Autologous hematopoietic stem-cell transplantation in neurological disorders: current approach and future directions. *Expert Rev Neurother*. 2020;20(12):1299-313.
26. Das J, Snowden J, Burman J, Freedman M, Atkins H, Bowman M, et al. Autologous haematopoietic stem cell transplantation as a first-line disease-modifying therapy in patients with 'aggressive' multiple sclerosis. *Multiple Sclerosis Journal*. 2021;27(8):1198-204.
27. Burt RK, Balabanov R, Tavee J, Han X, Sufit R, Ajroud-Driss S, et al. Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy. *Journal of Neurology*. 2020;267(11):3378-91.
28. Brittain G, Burt RK, Sharrack B. Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy (1st ed). In: Burt RK, Farge D, Ruiz MA, Saccardi R, A. SJ, editors. *Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases*. 1st Edition ed: CRC Press; 2021. p. 11.
29. Greco R, Bondanza A, Oliveira MC, Badoglio M, Burman J, Piehl F, et al. Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party. *Multiple Sclerosis Journal*. 2015;21(2):189-97.
30. Burt RK, Balabanov R, Han X, Quigley K, Arnautovic I, Helenowski I, et al. Autologous Hematopoietic Stem Cell Transplantation for Stiff-Person Spectrum Disorder: A Clinical Trial. *Neurology*. 2021;96(6):e817-e30.
31. Sormani MP, Muraro PA, Schiavetti I, Signori A, Laroni A, Saccardi R, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis. *Neurology*. 2017;88(22):2115-22.

32. Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. *The Lancet*. 2018;391(10127):1263-73.
33. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results. *Neurology*. 2001;56(11):1496-504.
34. Mariottini A, Bulgarini G, Forci B, Innocenti C, Mealli F, Mattei A, et al. Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis. *Eur J Neurol*. 2022;29(6):1708-18.
35. Moore JJ, Massey JC, Ford CD, Khoo ML, Zaunders JJ, Hendrawan K, et al. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2019;90(5):514-21.
36. Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, De La Camara R, et al. Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. *Bone Marrow Transplantation*. 2022.
37. Sharrack BP, Jennifer, Coles A, Snowden JA. Is stem cell transplantation safe and effective in multiple sclerosis? *BMJ*. (in press).
38. Kass-Iliyya L, Snowden JA, Thorpe A, Jessop H, Chantry AD, Sarrigiannis PG, et al. Autologous haematopoietic stem cell transplantation for refractory stiff-person syndrome: the UK experience. *Journal of Neurology*. 2021;268(1):265-75.
39. Burman J, Tolf A, Hägglund H, Askmark H. Autologous haematopoietic stem cell transplantation for neurological diseases. *Journal of Neurology, Neurosurgery & Psychiatry*. 2018;89(2):147-55.
40. Burt RK, Tappenden P, Han X, Quigley K, Arnautovic I, Sharrack B, et al. Health economics and patient outcomes of hematopoietic stem cell transplantation versus disease-modifying therapies for relapsing remitting multiple sclerosis in the United States of America. *Multiple Sclerosis and Related Disorders*. 2020;45:102404.
41. British National Formulary (online) London: BMJ Group and Pharmaceutical Press [Internet]. 2022 [cited 09/06/2022]. Available from: <http://www.medicinescomplete.com>.
42. Mahdi-Rogers M, McCrone P, Hughes RAC. Economic costs and quality of life in chronic inflammatory neuropathies in southeast England. *European Journal of Neurology*. 2014;21(1):34-9.
43. Health Technology Wales. Autologous haematopoietic stem cell transplantation to treat people with previously treated relapsing remitting multiple sclerosis (GUI019). 2020. p. 6.
44. Scottish Health Technologies Group. Autologous haematopoietic stem cell transplant for patients with highly active relapsing remitting multiple sclerosis not responding to high efficacy disease modifying therapies. 2019. p. 54.